Mentrik Biotech, LLC
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies (NCT01858181) | Mentrik Biotech, LLC | 2015-01-01 |
Track Mentrik Biotech, LLC automatically
Every clearance here is in the API, with alerts when new ones post.